Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Authors:
Open Access
- 23 February 2017
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 77 (5) , 493-503
Abstract
The complexity of neural circuits that control food intake and energy balance in the hypothalamic nuclei explains some of the constraints involved in the prevention and treatment of obesity. Two major neuronal populations present in the arcuate nucleus control caloric intake and energy expenditure: one population co-expresses orexigenic agouti-related peptide (AgRP) and neuropeptide Y and the other expresses the anorexigenic anorectic neuropeptides proopiomelanocortin and cocaine- and amphetamine-regulated transcript (POMC/CART). In addition to integrating signals from neurotransmitters and hormones, the hypothalamic systems that regulate energy homeostasis are affected by nutrients. Fat-rich diets, for instance, elicit hypothalamic inflammation (reactive activation and proliferation of microglia, a condition named gliosis). This process generates resistance to the anorexigenic hormones leptin and insulin, contributing to the genesis of obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have increasingly been used to treat type 2 diabetes mellitus. One compound (liraglutide) was recently approved for the treatment of obesity. Although most studies suggest that GLP-1RAs promote weight loss mainly due to their inhibitory effect on food intake, other central effects that have been described for native GLP-1 and some GLP-1RAs in rodents and humans encourage future clinical trials to explore additional mechanisms that potentially underlie the beneficial effects observed with this drug class. In this article we review the most relevant data exploring the mechanisms involved in the effects of GLP-1RAs in the brain–adipocyte axis.Keywords
This publication has 86 references indexed in Scilit:
- Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography studyHepatology, 2016
- Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 DiabetesDiabetes Care, 2015
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementNew England Journal of Medicine, 2015
- Exendin-4 improves thermogenic capacity by regulating fat metabolism on brown adipose tissue in mice with diet-induced obesity.2015
- Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weightJournal of Clinical Investigation, 2014
- Exendin-4 Improves β-Cell Function in Autophagy-Deficient β-CellsEndocrinology, 2013
- Hormones and diet, but not body weight, control hypothalamic microglial activityGlia, 2013
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adultsInternational Journal of Obesity, 2013
- Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor SignalingDiabetes, 2012
- Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic ratsClinical Science, 2012